皮质类固醇与氯巴占治疗伴ESES的癫痫性脑病:欧洲多中心随机对照试验
本研究为欧洲多中心开放标签平行组随机对照试验,计划纳入130例2至12岁伴ESES的癫痫性脑病患者,按1:1随机接受皮质类固醇或口服氯巴占治疗6个月,主要比较6个月后认知功能,次要结局包括18个月认知、睡眠EEG异常、安全耐受性及发作频率,并探索血清炎症介质和自身抗体对治疗反应的预测价值。
要点
- 皮质类固醇与氯巴占是伴ESES癫痫性脑病最常用的两种药物治疗。
- 主要结局为治疗6个月后认知功能,随访至18个月。
- 将探索血清炎症介质和自身抗体作为治疗反应生物标志物。
核心结论
- 该试验旨在比较皮质类固醇与氯巴占对伴ESES的癫痫性脑病患者认知功能的影响,并探索治疗反应的生物标志物。
研究设计与样本
- 欧洲多中心开放标签平行组随机对照试验,计划纳入130例2至12岁伴ESES的癫痫性脑病患者,按1:1随机分组。
关键数值与推荐
- 干预为皮质类固醇(每月静脉甲泼尼龙冲击或每日口服泼尼松龙)或口服氯巴占,疗程6个月。
- 主要结局为治疗6个月后认知功能,次要结局包括18个月认知功能、睡眠EEG异常、安全耐受性及发作频率。
- 在治疗前和治疗开始后8个月采集血样检测细胞因子和自身抗体。
临床怎么用
- 若研究证实某一治疗优于另一治疗或识别出治疗反应生物标志物,结果将指导临床医生对该严重癫痫综合征的早期治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epileptic encephalopathy with electrical status epilepticus in sleep (ESES) is an epilepsy syndrome occurring almost exclusively in children, usually at an age between 4 and 12 years. It is characterised by abundant sleep-induced epileptic activity in the electroencephalogram (EEG) and by acquired cognitive and behavioural deficits. The goal of treatment is to prevent further decline or even improve cognitive functioning. Based on mostly small and retrospective studies, corticosteroids and clobazam are regarded by many clinicians as the most effective pharmacological treatments. This European multicentre randomised controlled trial is designed to compare the effects of corticosteroids and clobazam on cognitive functioning after 6 months. Secondary outcomes include cognitive functioning after 18 months, EEG abnormalities in sleep, safety and tolerability, and seizure frequency. We also aimed at investigating whether treatment response in epileptic encephalopathy with ESES can be predicted by measurement of inflammatory mediators and autoantibodies in serum. METHODS: The pragmatic study will be performed in centres with expertise in the treatment of rare paediatric epilepsy syndromes across Europe. A total of 130 patients, 2 to 12 years of age, with epileptic encephalopathy with ESES will be enrolled and randomised in a 1:1 ratio to receive either corticosteroids (monthly intravenous methylprednisolone pulses or daily oral prednisolone) or oral clobazam for 6 months according to an open-label parallel-group design. Follow-up visits with clinical assessment, EEGs, and neuropsychological testing are scheduled for up to 18 months. Blood samples for cytokine and autoantibody testing are obtained before treatment and 8 months after treatment initiation. DISCUSSION: The treatment of epileptic encephalopathy with ESES aims at improving cognitive outcome. This randomised controlled study will compare the most frequently used treatments, i.e. corticosteroids and clobazam. If the study proves superiority of one treatment over the other or identifies biomarkers of treatment response, results will guide clinicians in the early treatment of this severe epilepsy syndrome. TRIAL REGISTRATION: ISRCTN, ISRCTN42686094 . Registered on 24 May 2013.
引用
- van den Munckhof B, Arzimanoglou A, Perucca E, et al. Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*). Trials. 2020. PMID: 33228736. doi:10.1186/s13063-020-04874-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。